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Purpose of the study
Ritonavir-boosted lopinavir (LPV/r) or nevirapine (NVP)
combined with two nucleosides are recommended for
first-line regimens in antiretroviral-naïve HIV-1 patients.
There are few comparative studies between these differ-
ent class-based regimens. Efficacy and safety may vary
from randomized studies to actual clinical practice.
Methods
We analyzed retrospective data from 167 HIV-1 infected
antiretroviral-naïve individuals initiating LPV/r or NVP
plus two nucleoside transcriptase reverse inhibitors
(NRTI) (between 1999 and 2006), according to current
guidelines.
Summary of results
LPV/r was given to 46.7%, whereas 53.3% received NVP.
Average patient age was 42 years (range, 19-80), 23.4%
were women and 72.5% Caucasians. Co-infection with
hepatitis viruses was present in 34.1% of all patients. The
f i r s tm o s tf r e q u e n t l yu s e dN R T Ib a c k b o n ew a sz i d o v u -
dine-lamivudine (84.4% all patients; 38.3% LPV/r; 46.1%
NVP). An alteration on NRTI backbone without study-
drug discontinuation was permitted. There were no sta-
tistically significant differences between groups in the
former baseline variables. Patients receiving a LPV/
r-based regimen had, in average, lower baseline T CD4
cell counts (P=0.004, Mann-Withney) and a higher viral
load (P<0.0001, Mann-Withney) compared with those
receiving NVP. Early response to treatment was evaluated
by the number of patients with a viral load decline >1.0
log10 after one month of treatment: 91.7% for LPV/r
(n=33/36) and 77.1% for NVP (n=27/35). Undetectable
viral load after one year of treatment was 79.3% for LPV/
r (n=46/58) and 82.8% for NVP (n=48/58); with an
increase in T CD4 cell count by 8.9 and 1.9-fold for LPV/
r (n=46) and NVP (n=54), respectively (P=0.003). The
overall number of patients that discontinued therapy
before completing one year of treatment were, respec-
tively for LPV/r and NVP, 17.9% (n=14/78) and 23.6%
(n=21/89). Toxicity was the most referred reason for
study-drug discontinuation in both groups. After one
year of treatment, toxicity grade III/IV blood biochemis-
try analyzed values (serum transaminases, total choles-
terol, HDL, LDL and triglycerides) were 10.2% (n=27/
264) for LPV/r and 8.33% (24/288) for NVP, compared to
6.44% (n=17/264) and 7.99 % (n=23/288) on baseline.
Conclusions
LPV/r seems to have a better early response and immu-
nological improvement. However, excluding the early
discontinuation of therapy due to toxicity, NVP seems
to have a lesser toxicity impact in the long-term.
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